The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

The Manufacturers Life Insurance Company purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 180,348 shares of the company’s stock, valued at approximately $3,313,000.

A number of other institutional investors have also made changes to their positions in VRDN. KBC Group NV bought a new stake in Viridian Therapeutics in the first quarter valued at about $34,000. ANTIPODES PARTNERS Ltd bought a new position in Viridian Therapeutics during the fourth quarter worth about $36,000. State of Wyoming bought a new position in Viridian Therapeutics during the second quarter worth about $43,000. Larson Financial Group LLC acquired a new position in shares of Viridian Therapeutics during the 3rd quarter worth about $52,000. Finally, US Bancorp DE increased its stake in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after acquiring an additional 463 shares during the last quarter.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

VRDN has been the topic of several recent analyst reports. Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wedbush lifted their price target on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Finally, Truist Financial boosted their price target on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.54.

Viridian Therapeutics Stock Down 0.6%

Viridian Therapeutics stock opened at $23.03 on Wednesday. The company has a market cap of $2.61 billion, a P/E ratio of -6.83 and a beta of 0.97. Viridian Therapeutics, Inc. has a 1-year low of $13.18 and a 1-year high of $34.29. The company has a fifty day simple moving average of $20.79 and a 200 day simple moving average of $20.59. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.